Annovis Bio, Inc. (ANVS) Balance Sheet
ANVS balance sheet, 2025
December 31, 2025 · U.S. dollars$21.1M assets = $4.2M liabilities + $16.9M equity
Both columns are drawn to the same scale: what ANVS owns equals what it owes plus shareholders’ equity. Hover a block for its value.
ANVS financial health
Descriptive bands, not a rating. Fiscal 2025.
ANVS balance sheet trends, 2012–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $2.8M2012 | $21.1M2025 | +25.0%/yr | |
| Total liabilities | $174,3632012 | $4.2M2025 | +42.5%/yr | |
| Shareholders’ equity | $2.7M2012 | $16.9M2025 | +22.8%/yr | |
| Cash & short-term investments | $72,3162012 | $19.5M2025 | +86.3%/yr | |
| Working capital | $1.4M2012 | $17.4M2025 | +$16.0M | |
| Book value per share | −$0.862023 | $0.822025 | — | |
| Current ratio | 9.142012 | 5.802025 | −3.34 | |
| Shares outstanding | 9.0M2023 | 20.6M2025 | +50.9%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
ANVS assets
ANVS liabilities and equity
ANVS debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
ANVS balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & short-term investments | $19.5M | $10.6M | $5.8M | $28.4M | $45.7M | $8.1M | $1,858 | $35,312 | $347,472 | $72,316 |
| Cash & equivalents | $19.5M | $10.6M | $5.8M | $28.4M | $45.7M | $8.1M | $1,858 | $35,312 | $347,472 | $72,316 |
| Short-term investments | — | $10.54B | — | — | — | — | — | — | — | — |
| Receivables | $0 | $0 | $0 | $0 | $0 | $0 | $735,075 | $0 | $0 | $1.5M |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | −$745.6M | $0 | $0 | $22,814 |
| Other current assets | $1.5M | $3.4M | $4.5M | $7.6M | $315,464 | $44,676 | $745.7M | $15,680 | $10,491 | $23,736 |
| Total current assets | $21.1M | $13.9M | $10.2M | $36.0M | $46.0M | $8.1M | $747,512 | $50,992 | $357,963 | $1.6M |
| Property, plant & equipment (net) | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $1.2M |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $0 | $0 | $0 | $0 | $0 | $0 | $369,595 | $0 | $0 | $65,090 |
| Total assets | $21.1M | $13.9M | $10.2M | $36.0M | $46.0M | $8.1M | $1.1M | $50,992 | $357,963 | $2.8M |
| Liabilities | ||||||||||
| Accounts payable | $2.6M | $2.3M | $1.3M | $4.0M | $688,074 | $341,856 | $1.2M | $68,425 | $71,107 | $174,363 |
| Total current liabilities | $3.6M | $3.9M | $4.3M | $7.7M | $1.5M | $578,380 | $2.0M | $567,943 | $490,220 | $174,363 |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $499,810 | $0 | $0 | $0 |
| Other long-term liabilities | $595,000 | $737,000 | $13.7M | $4.0M | $688,074 | $341,856 | $7.2M | $7.1M | $6.8M | $0 |
| Total liabilities | $4.2M | $4.6M | $18.0M | $7.7M | $1.5M | $578,380 | $9.7M | $7.6M | $7.3M | $174,363 |
| Shareholders' equity | ||||||||||
| Common stock & paid-in capital | $2,719 | $1,414 | $1,052 | $816 | $810 | $689 | $28 | $28 | $27 | $56,951 |
| Retained earnings (deficit) | −$163.7M | −$134.8M | −$110.3M | −$54.1M | −$28.7M | −$14.2M | −$8.8M | −$7.8M | −$7.1M | −$15.0M |
| Accumulated other comprehensive income | — | — | — | $0 | $0 | $0 | −$7.1M | −$7.1M | −$6.8M | — |
| Total shareholders' equity | $16.9M | $9.3M | −$7.8M | $28.3M | $44.5M | $7.5M | −$8.6M | −$7.6M | −$7.0M | $2.7M |
| Key figures | ||||||||||
| Total debt | — | — | — | — | — | — | $499,807 | — | — | — |
| Net cash (debt) | — | — | — | — | — | — | −$497,949 | — | — | — |
| Working capital | $17.4M | $10.0M | $5.9M | $28.3M | $44.5M | $7.5M | −$1.3M | −$516,951 | −$132,257 | $1.4M |
| Tangible book value | $16.9M | $9.3M | −$7.8M | $28.3M | $44.5M | $7.5M | −$8.6M | −$7.6M | −$7.0M | $1.5M |
| Book value per share | $0.82 | $0.76 | −$0.86 | — | — | — | — | — | — | — |
| Shares outstanding | 20.6M | 12.2M | 9.0M | — | — | — | — | — | — | — |
| Current ratio | 5.80 | 3.59 | 2.39 | 4.68 | 30.54 | 14.04 | 0.37 | 0.09 | 0.73 | 9.14 |
| Quick ratio | 5.37 | 2.72 | 1.34 | 3.69 | 30.33 | 13.96 | 0.37 | 0.06 | 0.71 | 8.87 |
| Equity / assets | 79.9% | 66.8% | −75.9% | 78.6% | 96.7% | 92.9% | −767.7% | −14,892.3% | −1,945.9% | 93.9% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $18.7M | $14.2M | $19.5M | $15.3M | $17.1M | $22.2M | $10.6M | $12.6M | $4.0M | $3.1M | $5.8M | $6.4M |
| Cash & equivalents | $18.7M | $14.2M | $19.5M | $15.3M | $17.1M | $22.2M | $10.6M | $12.6M | $4.0M | $3.1M | $5.8M | $6.4M |
| Short-term investments | — | — | — | — | — | — | — | $12.62B | — | — | — | — |
| Receivables | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $0 | $2.0M | $1.5M | $1.9M | $4.3M | $4.5M | $3.4M | $1.7M | $1.0M | $4.7M | $4.5M | $3.9M |
| Total current assets | $18.7M | $16.2M | $21.1M | $17.2M | $21.5M | $26.7M | $13.9M | $14.4M | $5.0M | $7.8M | $10.2M | $10.2M |
| Property, plant & equipment (net) | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $3.3M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total assets | $22.0M | $16.2M | $21.1M | $17.2M | $21.5M | $26.7M | $13.9M | $14.4M | $5.0M | $7.8M | $10.2M | $10.2M |
| Liabilities | ||||||||||||
| Accounts payable | $3.3M | $5.3M | $2.6M | $2.1M | $974,311 | $1.4M | $2.3M | $4.1M | $3.4M | $4.1M | $1.3M | $1.9M |
| Total current liabilities | $6.4M | $12.8M | $3.6M | $3.7M | $2.8M | $2.5M | $3.9M | $5.4M | $4.1M | $4.9M | $4.3M | $3.6M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other long-term liabilities | $19.9M | $326,999 | $595,000 | $299,000 | $319,000 | $179,000 | $737,000 | $1.9M | $2.7M | $6.3M | $13.7M | $0 |
| Total liabilities | $26.3M | $13.1M | $4.2M | $4.0M | $3.1M | $2.7M | $4.6M | $7.3M | $6.8M | $11.2M | $18.0M | $3.6M |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $4,260 | $2,854 | $2,719 | $2,019 | $1,948 | $1,948 | $1,414 | $1,328 | $1,172 | $1,101 | $1,052 | $902 |
| Retained earnings (deficit) | −$196.1M | −$181.3M | −$163.7M | −$153.9M | −$146.6M | −$140.4M | −$134.8M | −$129.0M | −$116.3M | −$111.3M | −$110.3M | −$88.0M |
| Total shareholders' equity | −$4.3M | $3.1M | $16.9M | $13.2M | $18.3M | $24.1M | $9.3M | $7.1M | −$1.8M | −$3.4M | −$7.8M | $6.7M |
| Key figures | ||||||||||||
| Working capital | $12.4M | $3.5M | $17.4M | $13.5M | $18.6M | $24.2M | $10.0M | $9.0M | $989,116 | $2.9M | $5.9M | $6.7M |
| Tangible book value | −$4.3M | $3.1M | $16.9M | $13.2M | $18.3M | $24.1M | $9.3M | $7.1M | −$1.8M | −$3.4M | −$7.8M | $6.7M |
| Book value per share | −$0.11 | $0.11 | $0.68 | $0.67 | $0.94 | $1.38 | $0.67 | $0.54 | −$0.15 | −$0.32 | −$0.81 | $0.74 |
| Shares outstanding | 37.5M | 27.8M | 24.8M | 19.7M | 19.5M | 17.4M | 13.8M | 13.0M | 11.3M | 10.6M | 9.5M | 9.0M |
| Current ratio | 2.95 | 1.27 | 5.80 | 4.60 | 7.65 | 10.68 | 3.59 | 2.66 | 1.24 | 1.60 | 2.39 | 2.87 |
| Quick ratio | 2.95 | 1.11 | 5.37 | 4.09 | 6.11 | 8.88 | 2.72 | 2.34 | 0.99 | 0.64 | 1.34 | 1.78 |
| Equity / assets | −19.3% | 19.2% | 79.9% | 76.5% | 85.4% | 90.0% | 66.8% | 49.2% | −34.7% | −42.9% | −75.9% | 65.1% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 13, 2026); data from EODHD.
ANVS financial position
At the end of fiscal 2025 (December 31, 2025), Annovis Bio had total assets of $21.1 million (up 51.4% from a year earlier), total liabilities of $4.2 million and shareholders' equity of $16.9 million. Its current ratio was 5.80. In the latest quarter (ended June 30, 2026) total assets were $22.0 million and equity -$4.3 million.
Related: ANVS income statement, ANVS cash flow statement, ANVS key metrics. See the ANVS stock overview for the latest quote and news.
ANVS balance sheet FAQ
What are Annovis Bio's total assets?
Annovis Bio reported total assets of $21.1 million at the end of fiscal 2025 (December 31, 2025), compared with $13.9 million a year earlier.
How much cash does Annovis Bio have?
Annovis Bio held $19.5 million in cash and short-term investments at the end of fiscal 2025.
What is Annovis Bio's book value?
Annovis Bio's shareholders' equity (book value) was $16.9 million at the end of fiscal 2025, or $0.82 per share.
What is Annovis Bio's current ratio?
Annovis Bio had current assets of $21.1 million and current liabilities of $3.6 million, a current ratio of 5.80 (it can cover its short-term obligations).